Ashwagandha (Withania somnifera) is the best-selling adaptogenic herb in the United States, with $184 million in retail sales in 2023 according to the American Botanical Council. Dr. K. Chandrasekhar, a clinical endocrinologist at the Asha Hospital in Hyderabad, published the most influential modern ashwagandha trial (Indian Journal of Psychological Medicine, 2012, n=64, double-blind RCT), demonstrating a 27.9% reduction in serum cortisol and a 69% reduction in perceived stress with 600 mg daily of full-spectrum root extract. Its use in Ayurvedic medicine spans approximately 3,000 years. The modern clinical evidence, while more recent, is becoming specific enough to evaluate properly.
Stress and anxiety reduction show the strongest evidence. A 2022 systematic review and meta-analysis in the Journal of Ethnopharmacology (k=12 RCTs, n=1,002) led by Dr. Adrian Lopresti at Murdoch University found significant reductions in perceived stress (Cohen's d = 1.10 on the PSS scale) and morning serum cortisol levels (d = 0.46, corresponding to an average reduction of 23%). Dr. Lopresti notes that these are clinically meaningful effect sizes — the stress reduction is comparable to first-line anxiolytic medications.
Sleep improvement is the second-strongest endpoint. Dr. Deepak Langade at the D. Y. Patil University School of Medicine conducted the largest trial to date (n=144, randomized, double-blind), finding that 600 mg daily improved sleep quality scores by 72% over 8 weeks, with effects beginning at week 2. Sleep onset latency decreased by an average of 14 minutes. The proposed mechanism involves dual action: GABA-mimetic activity (demonstrated in preclinical models at Banaras Hindu University) and HPA axis modulation through cortisol suppression.
Testosterone and exercise performance claims are weaker. A 2023 meta-analysis in Phytomedicine (k=4 RCTs, n=318) found a statistically significant but modest testosterone increase of 14.7% — however, this did not consistently translate to improved body composition or strength gains. Exercise performance improvements (VO2max, recovery time) are small (3-5%) and derived from trials with high risk of bias and small sample sizes.
Safety: generally well-tolerated at 300-600 mg daily for up to 12 weeks in clinical trials. However, Dr. Victor Navarro, chair of the DILI Network hepatology committee at Einstein Healthcare Network, reported 16 cases of hepatotoxicity associated with ashwagandha between 2017 and 2023, most involving doses above manufacturer recommendations. A 2023 Hepatology review by Dr. Navarro's group identified ashwagandha as the most common herbal cause of drug-induced liver injury in the US, prompting USP to add a cautionary label requirement. It may potentiate thyroid hormone levels by 10-15%, as documented by Dr. Ashok Sharma at Jaipur National University (Journal of Alternative and Complementary Medicine, 2018, n=50) — relevant for anyone with thyroid conditions or taking levothyroxine. Contraindicated in pregnancy due to potential abortifacient properties documented in animal studies.
The honest summary: credible, replicated evidence for stress and anxiety reduction, moderate but growing evidence for sleep quality improvement, and insufficient evidence for testosterone or exercise performance benefits. Choose a third-party tested product (look for USP, NSF, or ConsumerLab verification) standardized to at least 5% withanolides at 300-600 mg daily, and evaluate efficacy after a minimum of 8 weeks of consistent use.